Medicenna Therapeutics Corp (TSE:MDNA) has released an update.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Medicenna Therapeutics Corp announced that updated clinical data from its Phase 1/2 ABILITY-1 study will be presented at the 2024 Immunotherapy Bridge Conference. The study evaluates MDNA11, an innovative IL-2 super-agonist, in treating advanced solid tumors. This development underscores Medicenna’s commitment to advancing cancer immunotherapies.
For further insights into TSE:MDNA stock, check out TipRanks’ Stock Analysis page.
